Indication: Neuroendocrine Tumours

Patients: neuroendocrine tumours of the gastroenteropancreatic and bronchial tract, pheochromocytoma, paraganglioma, neuroblastoma, meningioma, or medullary thyroid carcinoma highly-expressing somatostatin receptors (SSTR), especially SSTRsubtype 2 (SSTR2), .

In general, patients should have one of the following to receive peptide receptor radionuclide therapy (PRRT) [1,2]:

• A progressive tumour as assessed by morphological imaging.

• Non-progressive extensive disease in two or more organs, and progressive disease in other sites that is likely to be uncontrolled.

• Clinically uncontrollable symptoms using the best standard of care.

• Inoperable disease, although surgery can be reconsidered after successful PRRT.